New targeted drug with radiation for locally advanced pancreatic cancer
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This Phase 1/2 trial tests adding peposertib, a targeted anti-cancer drug, to standard radiation for people with locally advanced pancreatic adenocarcinoma. It aims to improve control of the cancer after initial chemotherapy and determine whether the combo is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have pancreatic adenocarcinoma confirmed by pathology; other pancreas tumor types are not allowed
- You finished 4–6 months of standard chemotherapy (FOLFIRINOX, NALIRIFOX, or gemcitabine plus Abraxane) before starting this trial
- Your scans show locally advanced pancreatic cancer (not spread to distant organs) and a tumor board confirms non-surgery treatment
- Your cancer must have measurable disease on scan (RECIST 1.1) and your performance status must be ECOG 0–2
- Your blood counts and organ tests (liver, kidney, bilirubin) must meet specific minimum lab values
- You must be able to take oral study medicine and follow study visits, including agreeing to informed consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether combining targeted radiation with an at-home “tumor treating fields” device can better control locally advanced pancreatic cancer. It may help by attacking cancer cells in more than one way after prior chemotherapy.
This trial tests a special, high-dose radiation treatment for pancreatic cancer that has not spread but cannot be removed with surgery. The goal is to shrink the tumor and improve control of the cancer in the abdomen.
This early-phase trial tests how well targeted medicines (and possibly an immunotherapy drug) work for people with pancreatic cancer that can’t be fully removed with surgery or has spread. It also looks at whether the treatment is safe and can shrink or control tumors by blocking specific cancer pathways.
This Phase 2 trial tests giving specific chemotherapy in sequence, then using MRI-guided focused radiation to treat locally advanced, non-removable pancreatic cancer. It may help shrink or control the tumor while aiming radiation more precisely using MRI.
This trial tests whether giving a higher dose of radiation to the pancreas is safe and effective for people with locally advanced pancreatic cancer who have already had chemotherapy without progression.
This trial tests a combination of targeted radiation and two oral drugs (defactinib and avutometinib) for people with advanced pancreatic cancer that hasn't spread to distant organs. It may be an option if you've already had at least 2 months of chemo and your cancer is still locally advanced or borderline resectable.
Hear when a new Locally Advanced Pancreatic Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.